Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Glass Ceiling Report
- Law360 400
- NEWDiversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
Daiichi Sankyo, Inc. v. Seagen Inc.
Case Number:
Case Type:
PGR
Status:
Institution Denied
Petitioner:
Daiichi Sankyo, Inc.
Patent Owner:
Seagen Inc.
Patent Number:
Tech Center:
1600
-
Filed: December 23, 2020 00:00
Coverage
-
July 18, 2022
Seagen Gets PGR Nixed Under Fintiv In Rehearing Decision
Seagen Inc. has persuaded the Patent Trial and Appeal Board on rehearing to deny a challenge from Daiichi Sankyo Inc. and AstraZeneca Pharmaceuticals LP to its cancer antibody patent, with the board saying the post-grant review is no longer warranted under the controversial Fintiv precedent.
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
- Search PTAB cases and full-text documents.
- Download filings with the U.S. Patent & Trademark Office’s Patent Trial & Appeal Board.
- Set up alerts on new cases, follow ongoing cases, track new decisions and so much more!
TRY LAW360 FREE FOR SEVEN DAYS
View the PTAB case documentsAlready a subscriber? Click here to login
-
July 18, 2022